On 1st July 2021, SOTIO a.s. was split into two separate entities SOTIO a.s. and SOTIO Biotech a.s. Technical operations & Manufacturing division remain under the name SOTIO a.s. The company became a stand-alone contract manufacturing organization offering full GMP services covering production of Advanced Therapy Medicinal Products (ATMPs) including genetically modified and viral vectors.
Ludek Sojka, former Chief Technology Officer in SOTIO, was appointed as the Chief Executive Officer of SOTIO a.s. He has been with the company since its very beginning in 2010, responsible for technical operations and technical transfer from headquarters to affiliated companies in other countries.
Activities related to clinical development of innovative treatment methods for patients with cancer and support functions were allocated into the newly established company SOTIO Biotech a.s. led by Chief Executive Officer Radek Spisek. Both companies are part of PPF Biotech network.